Compare Manchester United PLC (MANU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs GeneDx Holdings Corp — how do they compare? Manchester United PLC trades at $20.51 (market cap $3.51B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Manchester United PLC is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and GeneDx Holdings Corp for 19 Days on average.
| MANU | WGS | |
|---|---|---|
Market Cap | $3.51B | $2.02B |
Volume | 412,769 | 734,640 |
Sector | Media | Health |
52-Week High | $24.19 | $167.51 |
52-Week Low | $15.20 | $34.51 |
Typical Hold Time | 109 Days | 19 Days |
Enterprise Value | $4.33B | $2.05B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.32, up 0.35% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but persistent net losses (-$33.02M) and negative margins. Analyst sentiment is divided with 40% buy ratings while technical indicators show selling pressure outweighing buying signals 10-5.
The stock presents a valuation opportunity with P/S of 3.9x below sports franchise peers, but faces execution risks from consistent losses and high debt. Upside depends on Champions League revenue conversion while downside risks include ongoing profitability challenges in the competitive Premier League landscape.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
